Nuvation Bio is trading at $4.49, down 5.47%, with no fresh company-specific catalyst identified for the October 16 decline.
- The move is consistent with pressure across biotech and risk-sensitive stocks; XBI is down 2.06%, and the Nasdaq is also lower.
- Sector and broader-market weakness is the likeliest context, but does not establish a direct cause.
- Citi’s Buy rating is supportive, not an evident cause; the supplied recent close was $4.75 on October 15.